A striking image of the Zepbound injection pen, Eli Lilly’s revolutionary weight loss medication, is showcased in the vibrant city of New York, USA, on December 11, 2023.
Captured by the talented Brendan McDermid | Reuters
The latest update on the Food and Drug Administration’s drug shortage database reveals that the majority of Eli Lilly’s sought-after weight loss drug Zepbound and its diabetes counterpart Mounjaro will face limited availability until the second quarter of this year due to surging demand.
With the exception of the 2.5-milligram versions, all other doses of Zepbound and Mounjaro are currently experiencing shortages. This update follows a previous announcement indicating restricted availability until April.
The persistent high demand for these groundbreaking weight loss and diabetes medications continues to outpace supply, despite efforts by Eli Lilly and its main competitor, Novo Nordisk, to ramp up production.
Patients are encountering difficulties in accessing these injectable treatments, which have become increasingly popular for their effectiveness in aiding significant weight loss…
2024-04-17 11:40:30
Read more on www.cnbc.com